Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Depemokimab (Brand name TBD) Expected FDA decision: December 16, 2025 Therapeutic use Depemokimab is under review for add-on maintenance treatment of eosinophilic asthma, a rare subtype of asthma, in patients age 12 years and older with type 2 inflammation
[1] [4] Rare but serious risks include pancreatitis and gallbladder disease
The agency may accept, change, or reject the committees recommendations and may explain timing or implementation conditions
In this multi-national, placebo-controlled study, major adverse cardiovascular events (MACE) including cardiovascular death, heart attacks, and strokes happened in 6.5% of participants taking Wegovy compared to 8% of those receiving placebo
To be precise about what that means: the brand states that thousands have explored or purchased the product
Research into permeation-enhancer formulations and alternate peptide backbones is active
